International Journal of Bio-Pharma Research <p>International Journal of Bio-Pharma Research (ISSN: 2287-6898) is an International, Monthly, Open Access,&nbsp;<strong>UGC</strong>&nbsp;<strong>Approved [63681]</strong>&nbsp;journal.</p> <p>IJBPR publishing the finest peer reviewed research in the fields of Biological and Pharmaceutical Sciences on the basis of its novelty, originality, importance, interdisciplinary interest and accessibility. Our objective is to inform authors of the decision on their manuscript (s) within one week of submission after&nbsp;<strong>Rigorous Peer Review</strong>. Following acceptance, a paper will normally be published in the next issue.</p> <p><strong>HIGHLIGHTS</strong></p> <p>&nbsp; &nbsp;UGC Approve Journal&nbsp;<strong>[63681].</strong></p> <p>&nbsp; &nbsp;Rapid publication service with precise review process.</p> <p>&nbsp; &nbsp;Assignment of DOI&nbsp;number with CrossRef.</p> <p>&nbsp; &nbsp;Indexed in worldwide abstracting agencies.</p> <p><strong>Manuscript Submissions</strong>:<br>Authors can submit their manuscript/s prepared in MS Word including Tables and Figures (If Any) at appropriate positions. All communications should be addressed to&nbsp;<strong></strong></p> International Journal of Biopharma and Research en-US International Journal of Bio-Pharma Research 2287-6898 <p><strong style="box-sizing: border-box; color: rgba(0, 0, 0, 0.87); font-family: &amp;quot; noto sans&amp;quot;,-apple-system,blinkmacsystemfont,&amp;quot;segoe ui&amp;quot;,&amp;quot;roboto&amp;quot;,&amp;quot;oxygen-sans&amp;quot;,&amp;quot;ubuntu&amp;quot;,&amp;quot;cantarell&amp;quot;,&amp;quot;helvetica neue&amp;quot;,sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: bolder; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px;">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</strong></p> Development and Biopharmaceutical Characterization of BCS Class II Drug – Naproxen by Two Way Complexation Solid Dispersion Technique <p>The objective of this study was to increase the solubility and bioavailability of Naproxen (NP) by fabricating ternary solid dispersion (tSDs) with water soluble polymer PEG 6000 and crospovidone. tSDs were prepared and optimized by 3<sup>2</sup> full factorial design with PEG 6000 level (X1) and CP level (X2) as independent variables and percent drug release (D80, (Y)) as dependent variable. The optimized tSDs were evaluated for their physicochemical properties which confirmed the formation of tSDs (DSC), SEM suggested smooth surface and compact structures. PXRD revels that drug was still present in crystalline form and was not molecularly dispersed in the complex especially in non-homogeneous part of the tSDs. The optimized tSDs revels that Dissolution rate (Y) was significantly affected by independent variable PEG 6000 (X1) while CP (X2) was insignificant. The transparent characteristics of tSDs was observed as a result of lowered Tg temperature gives higher dissolution rate up to 97.70 % for optimized formulation (F9). The pharmacokinetic study in Han Wistar rats showed that the tSDs had the greatest effect on oral bioavailability of NP <em>in vivo</em> test showed that NP (tSDs) presented significantly larger AUC<sub>0-t</sub>, which was 1.09 folds more than that of marketed formulation. C<sub>max</sub> of NP (tSDs) also increased from 120 µg/ml to 146 µg/ml compared to that of marketed formulations and generated shortened T<sub>max</sub> of (1.0 ± 0.416) h, compared to marketed dosage form (2.0 ± 0.456) h.</p> Milind Dharmraj Kamble Zahid Zaheer Santosh Mokale Rana Zainuddin ##submission.copyrightStatement## 2019-04-01 2019-04-01 8 4 2523 2530 10.21746/ijbpr.2019.8.4.1 Development and optimization of Etoposide loaded nanoparticles by using DoE response surface central composite design <p>Cancer is a leading cause of death globally. The World Health Organizationestimates that 9.6 million people died of cancer in 2018.&nbsp; More than 70% of all cancer deaths occur in low- and middle-income countries, where resources available for prevention, diagnosis and treatment of cancer are limited or nonexistent. Present investigation aimed at formulation and optimization of nanoparticles with Etoposide, an anticancer drug. Design Expert software is used for optimization. A randomised response surface design was used for optimization procedure. Stirring speed and crosslinking agent concentration are the independent variables for the dependant variables of particle size and drug loading. Statistical data of the dependent variables obtained were subjected to the analysis of variance and were found significant at p&lt;0.001 for particle size and at p&lt;0.0001 for drug loading. Encapsulation efficiency of the NPs was evaluated and they were found to be between 65.87±2.78 - 88.95±1.09. The prepared NPs are with the minimum size of 98±8.76nm and a maximum size of 786.24±6.89nm. Through factorial design, it was optimised that 500rpm (at a level of 1) and the maximum concentration of glutaraldehyde at 25% (at a level of 1) will result a least mean particle size of 150.13nm and maximum drug loading of 86.24%.</p> Bindu Madhavi Boddupalli Ramalingam Ramani Bhrugun Anisetti ##submission.copyrightStatement## 2019-04-01 2019-04-01 8 4 2531 2540 10.21746/aps.2018.8.4.2 Isolation and screening of glucose oxidase producing Aspergillus oryzae strain MF13 from marine source <p>Glucose Oxidase (GOx) received numerous applications in the food industry and clinical fields. Marine fungi extensively recognized for their ability to harvest enzyme source. In this study, we have made an effort to collect the sediment samples were collected from the coastal marine source of Karaikal, Puducherry, India. The isolated fungi features were characterized by morphological, physiological and molecular level. A total of 41 fungi isolated from marine soil, from that 8 isolates showed GOx activity. The active GOx producing isolates were selected through screening experiments. The particular isolate (MF13) genomic DNA was extracted. The extracted DNA was applied to be appropriate for Polymerase Chain Reaction (PCR), the amplification of target sequences in the 5.8S rRNA gene complex of internal transcribed spacer region (ITS1-ITS2). The ITS region of fungal rRNA is high importance for species-level identification of <em>A. oryzae</em> strain MF13 was found to be more reliable by comparative Genbank sequences. The potent <em>A. oryzae</em> was exhibited maximum cell biomass and GOx activity 3.50 g/L, 0.95 U/mg respectively. The present finding reveled GOx producing <em>A. oryzae</em> strain MF13 were found in marine source and beneficial for industrial applications.</p> Usha Devi Thangaprakasam Gangaiyammal Ayyasamy ##submission.copyrightStatement## 2019-04-01 2019-04-01 8 4 2541 2547 10.21746/ijbpr.2019.8.4.3